In the Original Investigation titled “Opioid Prescribing and Outcomes in Patients With Sickle Cell Disease Post–2016 CDC Guideline,” published online on March 11, 2024, and in the May 2024 issue, the study sample was inaccurately described. In the original article, the included study participants were referred to as individuals with sickle cell disease who were at least 1 year of age, had no cancer diagnosis, and had pharmacy coverage for the month of measurement. However, the participants included in the study were those who met these criteria and had at least 1 health care encounter (inpatient or outpatient) in the month. All data were reanalyzed using the sample described in the published article (ie, patients with sickle cell disease, regardless of their health care visit history). Corrections were made to the Key Points, Abstract, Results, Discussion, Table 2, Figures 1 to 3, eTables 3 to 7, and eFigures 2 and 4 to 6 in Supplement 1. The overall sample size remained unchanged, but the mean (range) number of patients included in each month was corrected, which impacted 4 outcomes that used monthly sample size as the denominator. In addition, the statistical significance of 2 outcomes shifted: the monthly opioid prescription rate lost statistical significance, and the monthly rate of pain-related emergency department visits gained statistical significance. The interpretations and conclusions of the study were not affected. The article was corrected online.

Read Full Article